Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

In both trials, lenacapavir was safe and generally well-tolerated. Two smaller Phase 2 studies are now evaluating lenacapavir and Truvada PrEP for cisgender women (PURPOSE 3) and people who inject ...

Gilead stock tumbled Wednesday on reports HHS could slash federal funding for HIV prevention, a staple in Gilead Sciences' ...

Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...

Descovy has been shown to be effective as PrEP in helping prevent HIV in a clinical study. People in the study took either Descovy or Truvada, which is another medication used for PrEP.

Gilead Sciences has said it plans to challenge patents held by the US government on the use of its HIV drug Truvada for pre-exposure prophylaxis (PrEP). In a move that will incense critics who ...

Like most prescribed medications, all three brands PrEP brands feature side effects. Here's how to prepare for them.

Updated coverage guidance under the Affordable Care Act: Long-acting PrEP. HIV.gov. October 2024. vi Centers for Disease Control and Prevention. Truvada for PrEP fact sheet: Ensuring safe and ...

Medicare has covered FDA-approved Pre-exposure Prophylaxis (PrEP) oral or injectable antiretroviral drugs such as Truvada, as well as counseling sessions for HIV risk assessment, medication ...